RT Journal Article
SR Electronic
T1 COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20109850
DO 10.1101/2020.05.22.20109850
A1 Sarah Heili-Frades
A1 Pablo Minguez
A1 Ignacio Mahillo Fernández
A1 Tomás Prieto-Rumeau
A1 Antonio Herrero González
A1 Lorena de la Fuente
A1 María Jesús Rodríguez Nieto
A1 Germán Peces-Barba Romero
A1 Mario Peces-Barba
A1 María del Pilar Carballosa de Miguel
A1 Itziar Fernández Ormaechea
A1 Alba Naya prieto
A1 Farah Ezzine de Blas
A1 Luis Jiménez Hiscock
A1 Cesar Perez Calvo
A1 Arnoldo Santos
A1 Luis Enrique Muñoz Alameda
A1 Fredeswinda Romero Bueno
A1 Miguel Górgolas Hernández-Mora
A1 Alfonso Cabello Úbeda
A1 Beatriz Álvarez Álvarez
A1 Elizabet Petkova
A1 Nerea Carrasco
A1 Dolores Martín Ríos
A1 Nicolás González Mangado
A1 Olga Sánchez Pernaute
A1 and the COVID FJD-TEAM
YR 2020
UL http://medrxiv.org/content/early/2020/05/25/2020.05.22.20109850.abstract
AB There is limited information describing features and outcomes of patients requiring hospitalization for COVID19 disease and still no treatments have clearly demonstrated efficacy.Demographics and clinical variables on admission, as well as laboratory markers and therapeutic interventions were extracted from electronic Clinical Records (eCR) in 4712 SARS-CoV2 infected patients attending 4 public Hospitals in Madrid. Patients were stratified according to age and stage of severity. Using multivariate logistic regression analysis, cut-off points that best discriminated mortality were obtained for each of the studied variables. Principal components analysis and a neural network (NN) algorithm were applied.A high mortality incidence associated to age >70, comorbidities (hypertension, neurological disorders and diabetes), altered vitals such as fever, heart rhythm disturbances or elevated systolic blood pressure, and alterations in several laboratory tests. Remarkably, analysis of therapeutic options either taken individually or in combination drew a universal relationship between the use of Cyclosporine A and better outcomes as also a benefit of tocilizumab and/or corticosteroids in critically ill patients.We present a large Spanish population-based study addressing factors influencing survival in current SARS CoV2 pandemic, with particular emphasis on the effectivity of treatments. In addition, we have generated an NN capable of identifying severity predictors of SARS CoV2. A rapid extraction and management of data protocol from eCR and artificial intelligence in-house implementations allowed us to perform almost real time monitoring of the outbreak evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study has no specific funding. AS has a Marie Sklodowska-Curie grant (#796721). LF is supported by ISCIII (CA18/00017). PM has a Miguel Servet contract funded by the ISCIII (CP16/00116).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey is a retrospective study with de-identified medical record data. No patient management protocols have been altered due to the study. The study was approved by our Institutional Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are available from the corresponding author on request.